Nephro Care India Ltd (NEPHROCARE) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Nephro Care India Ltd on NSE and BSE, with an AI summary of each filing.
NEPHRO CARE INDIA LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 12 Nov 2026, 5:30 am
Nephro Care India Schedules Board Meeting on 12th Nov'26 for Half-Yearly Results Nephro Care India Limited has scheduled a board of directors meeting on 12th Nov'26. The board will meet to consider, evaluate, and approve the company's half-yearly unaudited financial results for the period ended Sep'26, along with other general corporate matters.
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Intimation · 12 Nov 2026, 5:30 am
Nephro Care India Schedules Board Meeting for Q2 Results and Office Relocation Nephro Care India Limited has scheduled a Board of Directors meeting on 12th Nov'26 to consider and approve the unaudited standalone and consolidated financial results, along with profit/loss statements and cash flows for the quarter and half-year ended 30th Sep'26. The board will also review the Statutory Auditor's Limited Review Report and consider a proposal to shift the company's corporate office to LA Block, Sector 3, Bidhannagar, Kolkata.
SDD Certificate for the quarter ended 30th September 2026
Others (Uncategorized) · 05 Oct 2026, 9:08 pm
Nephro Care India Submits Full SDD Compliance for Quarter Ended Sep'26 Nephro Care India Limited submitted its Structured Digital Database (SDD) compliance certificate for the quarter ended 30th Sep'26, pursuant to SEBI Prohibition of Insider Trading Regulations. Issued by Practicing Company Secretary Saptasikha & Co., the certificate confirms that the company maintained a tamper-proof internal database with access controls and audit trails capable of retaining records for 8 years. All unpublished price-sensitive information was captured, including the one required event during the quarter, with zero non-compliances observed.
Nephro Care India Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the quarter ended 30th September 2026
Others (Uncategorized) · 01 Oct 2026, 6:52 pm
Nephro Care India Confirms Non-Applicability of SEBI Corporate Governance Provisions Nephro Care India Limited informed the exchange that Corporate Governance provisions under Regulation 27(2) of SEBI (LODR) Regulations, 2015, are not applicable to the company for the quarter ended 30th Sep'26. Having listed on the NSE EMERGE platform on 5th Jul'24, the company is exempt from specified corporate governance requirements under Regulation 15(2)(b), which excludes entities listed on SME exchanges. The company confirmed it will continue to comply with relevant listing requirements as and when applicable.
Nephro Care India Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 25, 2026. Further, the company has informed the Exchange regarding voting results.
Annual General Meeting · 28 Sept 2026, 11:50 pm
Nephro Care India Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 25, 2026
Annual General Meeting · 25 Sept 2026, 11:58 pm
Nephro Care India Limited has informed the Exchange about Closure of operations
Others (Uncategorized) · 08 Sept 2026, 5:27 pm
Nephro Care India to Discontinue Operations at Kolkata Dial a Dialysis Unit Nephro Care India Limited has decided to discontinue operations at its Dial a Dialysis (DAD) unit in Salt Lake City, Kolkata, operating under the brand name "Nephro Care India Ltd – DAD". The closure is driven by regulatory and licensing constraints alongside the non-availability of requisite statutory permissions. Consequently, the unit will cease all operations and vacate the premises effective 15th Sep'26.
The Exchange had sought clarification from Nephro Care India Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: The response of the Company is enclosed.
Others (Uncategorized) · 01 Sept 2026, 11:32 pm
Nephro Care Clarifies Identical Standalone and Consolidated Results for Q1 FY27 Nephro Care India clarified to the NSE on 29 Aug'26 that its identical standalone and consolidated results for the quarter ended 30 Jun'26 were due to its subsidiary's pre-operative status. The subsidiary, Vivacity Multiple Ventures, incorporated on 18 Dec'25, had not commenced commercial operations. Consequently, it reported NIL income and NIL profit after tax for the quarter. While its financials were considered for consolidation, the lack of revenue or profit resulted in no change to the group's reported figures, explaining the identical results.
The Exchange has sought clarification from Nephro Care India Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: The response of the Company is awaited.
Others (Uncategorized) · 28 Aug 2026, 5:42 pm
Nephro Care India Limited has informed the Exchange that Record date for the purpose of Annual General Meeting is 18-Sep-2026.
Annual General Meeting · 26 Aug 2026, 9:53 pm
Nephro Care India Limited has informed the Exchange regarding 'Intimation regarding Record date, Cut-off date for remote E-Voting & book closure date forthe ensuing 12th Annual General Meeting of the Company'.
Annual General Meeting · 26 Aug 2026, 9:48 pm
Nephro Care India Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 25, 2026
Annual General Meeting · 26 Aug 2026, 9:33 pm
Nephro Care India Limited has informed the Exchange regarding Outcome of Board Meeting held on August 07, 2026.
Outcome · 07 Aug 2026, 10:58 pm
Nephro Care Q1FY27 Results: Strong Revenue Growth and Turnaround to Profit Nephro Care India reported strong performance for Q1FY27, with consolidated revenue from operations at ₹2,918.52 lacs, up 68.4% YoY. The company posted a Profit After Tax of ₹160.79 lacs, a significant turnaround from a loss of ₹64.82 lacs in Q1FY26. Basic EPS for the quarter was ₹0.98. The Board also approved an O&M agreement for Malda Hospital and a business collaboration with Stone & Urology Clinic, Ranchi. The AGM is scheduled for 25th Sep'26. IPO funds are largely utilized, with ₹19.58 lacs remaining.
Nephro Care India Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
Others (Uncategorized) · 07 Aug 2026, 10:52 pm
Nephro Care: No Deviation in IPO Fund Utilization as of Jun'26 Nephro Care India confirms no deviation in the utilization of its IPO proceeds as of 30th Jun'26. Of the total funds, ₹2,615.34 lacs allocated for a multi-speciality hospital in Kolkata were fully utilized. From the ₹1,002.70 lacs designated for general corporate purposes, ₹983.12 lacs have been used, leaving an unutilized balance of ₹19.58 lacs. The statement was reviewed by the Audit Committee and Board on 07th Aug'26 and certified by statutory auditors.
Nephro Care India Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Outcome · 07 Aug 2026, 10:49 pm
Nephro Care India Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 2,919 (+68.4% YoY | +9.1% QoQ) ■ EBITDA: 362 (+500.2% YoY | +78.8% QoQ) ■ EBITDA Margin (%): 12.4 (+892 bps YoY | +483 bps QoQ) ■ PAT: 161 (Loss to Profit YoY | +60.1% QoQ) ■ EPS (INR): 0.98 (Loss to Profit YoY | +60.7% QoQ) Nephro Care India Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) Segmental Performance IPD Services ■ Revenue: 1,565 (+103.2% YoY | +13.9% QoQ) ■ EBITDA: 0.0 ■ EBITDA Margin (%): 0.0 OPD Services ■ Revenue: 758 (+33.8% YoY | +10.1% QoQ) ■ EBITDA: 0.0 ■ EBITDA Margin (%): 0.0 Sale of medicines from pharmacy ■ Revenue: 595 (+50.2% YoY | -2.7% QoQ) ■ EBITDA: 0.0 ■ EBITDA Margin (%): 0.0
To consider other business matters
Intimation · 27 Jul 2026, 7:28 pm
Nephro Care India Board Meeting on 7th Aug'26 to Discuss Q1 Results, Strategy Nephro Care India's board will meet on 7th Aug'26 to approve Q1FY27 results (quarter ending 30th Jun'26). The agenda also includes key strategic decisions: discontinuing operations at Tulip Hospital, Ranchi, while executing new agreements for hospital operations in Malda with PRAJATNA HEALTHCARE & DIAGNOSTIC LLP and a business collaboration with Stone & Urology Clinic, Ranchi. The board will also approve the FY26 Directors' Report and fix the date for the 12th Annual General Meeting.
NEPHRO CARE INDIA LIMITED has informed the Exchange about Board Meeting to be held on 07-Aug-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended June 2026 and Other business.
Intimation · 07 Aug 2026, 5:30 am
Nephro Care India Sets Board Meeting for Q1FY27 Results Nephro Care India Ltd. has scheduled a board meeting for 07-Aug'26. The primary agenda is to consider and approve the unaudited financial results for the quarter ending Jun'26. Other unspecified business items will also be discussed.
SDD Compliance Certificate for the quarter ended 30th june 2026
Others (Uncategorized) · 16 Jul 2026, 4:52 pm
Nephro Care India Submits Insider Trading Compliance Certificate for Q1FY27 Nephro Care India Limited has submitted its Structured Digital Database (SDD) compliance certificate for the quarter ended 30th Jun'26, as required by SEBI's Insider Trading Regulations. The certificate, issued by a Practicing Company Secretary, confirms the company maintains a compliant, non-tamperable SDD to record Unpublished Price Sensitive Information (UPSI). It also verified that all required events for the quarter were captured, and no non-compliances were observed during the period, ensuring proper controls are in place.
Nephro Care India Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Q_ FY 20__-__
Others (Uncategorized) · 10 Jul 2026, 5:47 pm
Nephro Care Exempt from Corporate Governance Provisions Post-SME Listing Nephro Care India Limited, which listed on the NSE EMERGE Platform on 05 Jul'24, has informed the exchange that it is exempt from corporate governance compliance under Regulation 15(2)(b) of SEBI LODR Regulations, 2015. Consequently, provisions specified in regulations 17 to 27, among others, will not apply to the company for the quarter ended 30 Jun'26. This exemption is applicable to entities listed on SME exchanges. The company will adhere to other applicable listing compliances.
The Exchange had sought clarification from Nephro Care India Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Half Yearly figures not submitted by the Company The response of the Company is enclosed.
Others (Uncategorized) · 09 Jul 2026, 8:34 pm
SDD Compliance Certificate for the financial year ended 31st March 2026
Others (Uncategorized) · 25 Jun 2026, 8:42 pm
Nephro Care India Submits Insider Trading Compliance Certificate for FY26 Nephro Care India has submitted its Structured Digital Database (SDD) compliance certificate for the financial year ended 31st Mar'26, as required by SEBI's insider trading regulations. The filing, dated 25th Jun'26 and certified by a practising company secretary, confirms the company maintains a non-tamperable database with an audit trail to record Unpublished Price Sensitive Information (UPSI). The company captured all three required events during FY26 and reported no instances of non-compliance for the previous financial year.